FRANK-RECRUITMENT-GROUP
12.1.2021 16:02:33 CET | Business Wire | Press release
UK staffing firm Frank Recruitment Group has today announced the opening of its latest location in Geneva, Switzerland.
The new office is the cloud recruitment company's eighth in Europe, bringing its total number of global hubs to 21.
Frank Recruitment Group, founded in Newcastle upon Tyne in 2006 with just three members of staff, now employs almost 2,000 people worldwide and is part of Tenth Revolution Group, the global leader in cloud talent solutions. The Swiss location will add a number of new team members to that headcount, with plans to create up to 50 jobs within five years.
The move will see Frank Recruitment Group further increase its reach in Europe and enable the firm to better support its growing global client base.
With the country's technology market expanding fast, and digitalisation and cloud migration at the top of every Swiss CIO's agenda, demand for IT professionals to support transformation is mounting.
"Our new Swiss base will allow us to offer better support to our clients and partners in the region, at a time when specialist technology recruitment consulting is more needed than ever," said Director of Sales Paul Hanley, who will be leading the new location.
"We want to replicate the success we’ve achieved in other global regions here in Switzerland by solidifying our position as the leaders in cloud tech staffing solutions, and continue to enable digital transformation by delivering the best permanent and contract tech talent to businesses that need it," Hanley said.
"I'm especially proud to be launching our Swiss office," said Zoë Morris, Frank Recruitment Group President. "2020 was a challenging year for the staffing industry, so it feels like a special achievement to be opening a new location and growing our business at this time. We feel very privileged to be able to serve this exciting market and create new jobs in the area in the process."
Hanley added, "Our launch team is packed with seasoned, multi-lingual staffing experts, all of whom have significant experience within the Swiss recruitment industry. Our focus is entirely on the tech market, and that will allow us to deliver the kind of dedicated, specialist expertise that's been missing in the Swiss market so far. I'm incredibly excited to get to work in the market, and make a real impact for both businesses and tech professionals in the area by connecting the right people with the right jobs."
At the new location, Frank Recruitment Group will initially launch its Nigel Frank, Mason Frank, and FRG Technology Consulting brands, which recruit for Microsoft, Salesforce, and emerging technology specialists, respectively.
The Swiss office is based at 14 Rue du Rhône, Geneva.
Note to editors:
ABOUT FRANK RECRUITMENT GROUP
Frank Recruitment Group is a division of Tenth Revolution Group, the world’s leading experts in cloud talent solutions. Founded in Newcastle upon Tyne, in 2006, Frank Recruitment Group creates and delivers highly sought-after professionals in some of the industry’s most skills-scarce ecosystems.
The company employs nearly 2,000 people across 20 offices, including Dallas, New York, Philadelphia, San Francisco, Tampa, Denver, Scottsdale, Charlotte, and Irvine in the US. EMEA and APAC are served by nine offices across the UK, Germany, the Netherlands, Spain, and locations in Singapore and Australia.
The group operates seven trading brands that each focus on a specific technology product: Jefferson Frank (AWS), Nigel Frank International (Microsoft Dynamics and Azure), Mason Frank International (Salesforce), Washington Frank (enterprise ERP), Anderson Frank (NetSuite), Nelson Frank (ServiceNow), and FRG Technology Consulting (Marketing Automation and emerging technologies).
Frank Recruitment Group was named one of Europe’s fastest-growing companies and received recognition as one of the UK’s top 100 private companies with the fastest-growing profits . The group plans to expand its outreach globally and attract more trainee recruiters in strategic hubs to meet demand for its services.
For more information, visit: www.frankgroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005733/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
